These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37908689)

  • 1. Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China.
    Hu R; Liu Y; Zhang L; Kang G; Xu B; Li M; Yu J; Zhu Y; Guo H; Wang Z
    Front Public Health; 2023; 11():1272562. PubMed ID: 37908689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019.
    Gao J; Tang F; Wang Z; Yu J; Hu R; Liu L; Kang G
    Vaccine; 2021 Mar; 39(9):1415-1419. PubMed ID: 33541795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.
    Hu Y; Pan X; Chen F; Wang Y; Liang H; Shen L; Chen Y; Lv H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035141. PubMed ID: 35240930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The surveillance analysis of the adverse events following immunization of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine in Zhejiang Province].
    Hu Y; Huang Z; Wang Y; Liang H; Pan XJ; Chen YP; Yuan L; Yang SY; Chen JJ; Chen YY; Yan XM; Tao Q; Qin X; Lyu HK
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Nov; 56(11):1625-1629. PubMed ID: 36372754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.
    Hu R; Peng S; Liu Y; Tang F; Wang Z; Zhang L; Gao J; Guo H
    BMC Public Health; 2021 Jul; 21(1):1338. PubMed ID: 34229643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.
    Kang G; Tang F; Wang Z; Hu R; Yu J; Gao J
    Hum Vaccin Immunother; 2021 Aug; 17(8):2568-2574. PubMed ID: 33780310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.
    Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017.
    Li Z; Xu J; Tan H; Zhang C; Chen J; Ni L; Yun X; Huang Y; Wang W
    Int J Infect Dis; 2020 Oct; 99():149-155. PubMed ID: 32795602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of safety of haemophilus influenza type b(Hib) conjugate vaccine in postmarketing based on the immunization information management system].
    Wang Z; Ma F; Zhang J; Yu J; Kang G; Gao J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Jun; 49(6):475-80. PubMed ID: 26310329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of pneumococcal vaccines at the time of sequential schedule: data from surveillance of adverse events following 13-valent conjugated pneumococcal and 23-valent polysaccharidic pneumococcal vaccines in newborns and the elderly, in Puglia (Italy), 2013-2020.
    Di Lorenzo A; Martinelli A; Bianchi FP; Scazzi FL; Diella G; Tafuri S; Stefanizzi P
    Ann Ig; 2023; 35(4):459-467. PubMed ID: 36477097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021.
    Gao D; Dong G; Zhu L; Jia N; Sun B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.
    Lv H; Pan X; Liang H; Wang Y; Hu Y
    Hum Vaccin Immunother; 2021 Nov; 17(11):4617-4622. PubMed ID: 34491888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following immunization with bivalent oral poliovirus vaccine in Jiangsu, China.
    Gao J; Kang G; Hu R; Zhang L; Yu J; Wang Z; Tang F
    Br J Clin Pharmacol; 2021 Dec; 87(12):4831-4838. PubMed ID: 34240463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China.
    Wang C; Huang N; Lu QB; Black S; Liang X; Cui F
    Front Immunol; 2022; 13():956473. PubMed ID: 36248783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.